Cardiometabolic Health Congress (CMHC 2012)


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Cardiometabolic Health Congress (CMHC 2012)

  1. 1. Final Announcement: Register by 9/14 & Save up to $300! October 10–13, 2012 • Westin Boston Waterfront • Boston, MA The 7th Annual CMHC is the Premier Multidisciplinary Congress Providing the Best Cardiometabolic Science & Clinical Education Šƒ‹”’‡”•‘• George L. Bakris, MD Christie M. Ballantyne, MD Robert H. Eckel, MD Jay S. Skyler, MD, MACP ‹•–‹‰—‹•Š‡† ƒ…—Ž–› Lawrence Appel, MD, MPH Keith Ferdinand, MD Luigi Meneghini, MD Domenic Sica, MD Louis Aronne, MD Vivian Fonseca, MD Suzanne Oparil, MD Steven Smith, MD Timothy Bailey, MD JoAnne Foody, MD Anne Peters, MD Allan Sniderman, MD Harold Bays, MD W. Timothy Garvey, MD Jorge Plutzky, MD Gregg Stone, MD Richard Bergenstal, MD James Gavin III, MD, PhD Richard Pratley, MD Neil Stone, MD, MACP Peter Berger, MD Thomas Giles, MD Matthew Riddle, MD Addison Taylor, MD, PhD Deepak L. Bhatt, MD, MPH Allison Goldfine, MD Paul Ridker, MD, MPH Peter Toth, MD, PhD Ron Blankstein, MD Irl Hirsch, MD Matthew Roe, MD Sotirios Tsimikas, MD Robert Busch, MD Silvio Inzucchi, MD Julio Rosenstock, MD James A. Underberg, MD Christopher Cannon, MD Terry Jacobson, MD Francesco Rubino, MD Alan Weder, MD Robert Chilton, MD Lee M. Kaplan, MD, PhD Donna Ryan, MD William White, MD William Cromwell, MD Robert Kushner, MD Marc Sabatine, MD, MPH Stephen Wiviott, MD Michael Davidson, MD Peter Libby, MD Ernst Schaefer, MD Carol Wysham, MD Sergio Fazio, MD, PhD Peter McCullough, MD, MPH Arya Sharma, MD, PhD Bernard Zinman, MD”ƒ•Žƒ–‹‰ …—––‹‰Ǧ‡†‰‡ •…‹‡…‡ ‹–‘ ”‡ƒŽǦ™‘”Ž† ’”ƒ…–‹…ƒŽ •‘Ž—–‹‘• …ƒ Š‡”‡ –‘ ”‡‰‹•–‡”–Šƒ– ™‹ŽŽ —†‘—„–‡†Ž› ƒ‡ ƒ •‹‰‹ϐ‹…ƒ– ‹’ƒ…– ‘ ›‘—” †ƒ‹Ž› ’”ƒ…–‹…‡ ˆ‘” –Š‡ ™™™Ǥ…ƒ”†‹‘‡–ƒ„‘Ž‹…Š‡ƒŽ–ŠǤ‘”‰ This activity is jointly sponsored by HealthScience Media, Inc. (HSM), and Medical Education Resources, Inc. (MER).
  2. 2. ͚͙͚͘ k assessment, Dear Colleague : n it comes to ris etab olic disease whe ence addresses the breadth vascular from m tidisciplinary confer separate cardio ul ss (CMHC) – It is impossible to inical intervention. No other m rdiometabolic Health Congre olic risk. d cl Ca ab prevention, an paradigm like the 7th Annual sential to combat cardiomet is es and depth of th ientific basis and clinical tools es to optimally imparting the sc clinical strategi impa rting real-world 2 diabetes, dyslipidemia, expert forum – uding obesity, type unprecedented incl e, and related The CMHC is an cardiometabolic risk factors mbosis, chronic kidney diseas le manage multip ute coronary syndrome, thro , ac atherosclerosis comorbidities. portunity to: will have the op and the immed iate By attending the CMHC, you nt clinical data er the most rece faculty to deciph with our expert le cardiovascul ar • Collaborate for your patients and practice. nts with multip implications ing complex patie tions for manag ence-based solu • Access evid ic risk factors. 14 complimenta ry and metabol 15 sessions and ng experience with ur CMHC learni • Customize yo oose from. HC exhibit hall. symposia to ch atured in the CM ts and services fe ng-edge produc • Preview cutti E credits. us medical • Earn 28.5 CM lty, 32 prestigio isis ld-renow ned expert facu combat the global health cr al ong with 60 wor agues – in our mission to Please join us – 1500 of your colle d disease. associations, an cardiovascular and metabolic emanating fro m in Boston! the 2012 CMHC d to your participation at We look forwar Best regards, Žƒ–›‡ǡ Š”‹•–‹‡ Ǥ ƒŽ of Medicine ”‹•ǡ Baylor College ‡‘”‰‡ Ǥ ƒ icago Medicin e The University of Ch ǡ ƒ› Ǥ ›Ž‡”ǡ University of Miami ‡Žǡ Medicine ‘„‡”– Ǥ … Miller School of University of Colorado ical Campus Anschutz Med “CMHC has evolved over a relatively short period to become a world-class meeting, now sufficiently established to attract the very best faculty and attendees, yet still small enough for meaningful interaction2 with presenters and faculty covering ‘soup to nuts’ – the spectrum of cardiometabolic issues.” − Darren McGuire, MD
  3. 3. ʹͲͳʹ ƒ”†‹‘‡–ƒ„‘Ž‹… ‡ƒŽ–Š ‘‰”‡•• Š‘ ––‡†• –Š‡ ǫ 2011 Attendees by Specialty 2011 Attendees by RegionPrimary Care Other Endocrinology New England North CentralInternal Medicine 5% 26% 13% 30% West 31% 15% South 15% Atlantic 12% 34% 19% South Central Cardiology Mid-Atlantic Contents ‡•–‹‘‹ƒŽ• Šƒ‹”’‡”•‘• Ƭ ƒ…—Ž–› Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ͷ Dz‘•– ’”ƒ…–‹…ƒŽ ƒ† —’Ǧ–‘Ǧ†ƒ–‡ …‘ˆ‡”‡…‡ Ž‹‹‰ …ƒ”†‹‘˜ƒ•…—Žƒ” †‹•‡ƒ•‡ ™‹–Š †‹ƒ„‡–‡• ƒ† Š›’‡”Ž‹’‹†‡‹ƒǤdz ‰‡†ƒ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ ͸ Stephen Podolsky, MD (West Roxbury, MA) ‘”’‘”ƒ–‡Ǧ—’’‘”–‡† Dz š…‡ŽŽ‡– …‘ˆ‡”‡…‡Ǩ ‡ŽŽ ‘”‰ƒ‹œ‡† ‹ –‡”• ‘ˆ …Š‘‘•‹‰ Ƭ ’‘•‘”‡† ›’‘•‹ƒ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ ͺ •’‡ƒ‡”• ƒ† –‘’‹…•Ǥ ‘˜‡† –Š‡ …ƒ•‡ †‹•…—••‹‘•Ǥ ‡ϔ‹‹–‡Ž› …‘‹‰ „ƒ… ‡š– ›‡ƒ”Ǩdz ”‘‰”ƒ ˜‡”˜‹‡™Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ ͳͲ Daisy Arce, MD (McAllen, TX) ……”‡†‹–ƒ–‹‘ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ ͳͳ Dz”‡ƒ– …Ž‹‹…ƒŽ –”‹ƒŽ —’†ƒ–‡• Ȃ ƒ Š‹‰ŠŽ‹‰Š– ‡˜‡”› –‹‡Ǥ ‡––‡” –Šƒ ƒ› ‘ˆ –Š‡ ™‡„•‹–‡•Ǥdz —’’‘”–‡”• Ƭ ’‘•‘”• Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ ͳʹ Dorothy Gohdes, MD (Albuquerque, NM) ʹͲͳʹ šŠ‹„‹–‘”• Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ ͳͶ DzŠ‡ …‘‰”‡•• ‡š…‡‡†‡† › ‡š’‡…–ƒ–‹‘•Ǥ —–•–ƒ†‹‰Ǩ ”ƒ˜‡Ž
  4. 4. ˆ‘”ƒ–‹‘ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ ͳͶ ‘ ƒ› –ƒ‡ǦŠ‘‡ ’‘‹–• –Šƒ–
  5. 5. ™‹ŽŽ •–ƒ”– ƒ’’Ž›‹‰ ‘†ƒ›Ǥdz Susan Perez, NP-C (Richfield, OH) ’‘•‘”•Š‹’ ’’‘”–—‹–‹‡• Ǥ Ǥ Ǥ ͳͶ Dz‡ƒŽŽ› ‡š…‡ŽŽ‡–ǡ ‘™Ž‡†‰‡ƒ„Ž‡ •’‡ƒ‡”•Ǥ ‡•– •‹‰Ž‡ ‡‰‹•–”ƒ–‹‘ ‘” Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ ͳͷ …‘ˆ‡”‡…‡ ‘ …ƒ”†‹‘‡–ƒ„‘Ž‹… ‹••—‡•Ǥdz Young Choi, MD (Fort Bragg, NC) Dz‘†‡”ˆ—Ž …‘ˆ‡”‡…‡Ǥ ‹– ƒŽŽ –Š‡ ƒŒ‘” ’‘‹–•ǡ ˜‡”› ™‡ŽŽ “The CMHC approach ‘”‰ƒ‹œ‡†ǡ ‰”‡ƒ– •’‡ƒ‡”•Ǥdz is truly exceptional as it Brian Shapiro, MD (Jacksonville, FL) brings together a high- quality mix of sophisticated DzŠ‹• ™ƒ• ƒ ˆƒ–ƒ•–‹… …‘ˆ‡”‡…‡ Ȃ ˜‡”› Š‹‰ŠǦŽ‡˜‡Ž •…‹‡…‡ –”ƒ•Žƒ–‡† clinical providers with cutting-edge ‹–‘ ’”ƒ…–‹…ƒŽ ‰—‹†ƒ…‡ –Šƒ–
  6. 6. …ƒ †‹”‡…–Ž› ƒ’’Ž› –‘ ’ƒ–‹‡– …ƒ”‡Ǩ investigators. CMHC is a meeting ‡•– …‘ˆ‡”‡…‡
  7. 7. Šƒ˜‡ ‡˜‡” „‡‡ –‘Ǩdz I look forward to each year.” Laura Waite, PharmD (Ocoee, FL) – Paul Ridker, MD Dz š…‡ŽŽ‡– Œ‘„ǡ ƒ†
  8. 8. ƒ’’”‡…‹ƒ–‡ –Š‡ …‘”‡ ’”‡•‡–ƒ–‹‘• ƒ† ‘˜‡”ƒŽŽ ƒ……‡••‹„‹Ž‹–› ‘ˆ •’‡ƒ‡”• –‘ “—‡•–‹‘•Ǥ • ƒ …Ž‹‹…‹ƒǡ
  9. 9. ˆ‘—† –Š‡ …‘ˆ‡”‡…‡ —…Š ‘”‡ —•‡ˆ—Ž –Šƒ „‡…ƒ—•‡ –Š‡ ’”‹ƒ”› ˆ‘…—• ‹• ‘ …Ž‹‹…ƒŽ ƒƒ‰‡‡–Ǥdz 3 Wendy Hawkins, MD (Houston, TX)
  10. 10. ʹͲͳʹ ƒ”†‹‘‡–ƒ„‘Ž‹… ‡ƒŽ–Š ‘‰”‡•• Šƒ‹”’‡”•‘• George L. Bakris, MD Christie M. Ballantyne, MD Professor of Medicine Professor of Medicine Director, ASH Comprehensive Hypertension Center Chief, Section of Atherosclerosis and Vascular Medicine The University of Chicago Medicine Department of Medicine, Baylor College of Medicine Director, Center for Cardiovascular Disease Prevention Methodist DeBakey Heart Vascular Center Baylor College of Medicine ‹•–‹‰—‹•Š‡† ƒ…—Ž–› Lawrence Appel, MD, MPH Louis Aronne, MD Timothy Bailey, MD Professor of Medicine, Epidemiology Director, Comprehensive Weight Control Program Clinical Associate Professor of Medicine International Health New York-Presbyterian Hospital University of California at San Diego Director, Welch Center for Prevention, Clinical Professor of Medicine Director, AMCR Institute Epidemiology Clinical Research Weill-Cornell Medical College Johns Hopkins Medical Institutions Harold Bays, MD Richard Bergenstal, MD Peter Berger, MD Medical Director/President Executive Director Chairman, Cardiology Louisville Metabolic and Atherosclerosis International Diabetes Center, Park Nicollet Director, Cardiovascular Center for Clinical Research Research Center, Inc. Clinical Professor Geisinger Health System Department of Medicine University of Minnesota Deepak L. Bhatt, MD, MPH Ron Blankstein, MD Robert Busch, MD Chief of Cardiology, VA Boston Healthcare System Co-Director Endocrinologist Director, Integrated Interventional CV Program Noninvasive Cardiovascular Imaging Fellowship The Endocrine Group Brigham and Women’s Hospital Brigham and Women’s Hospital Senior Investigator, TIMI Study Group Associate Professor, Harvard Medical School Christopher Cannon, MD Robert Chilton, MD William Cromwell, MD Senior Investigator, TIMI Study Group Professor of Medicine Adjunct Associate Professor Cardiovascular Division Director, Cardiac Catheterization Lab Hypertension and Vascular Disease Center Brigham and Women’s Hospital University of Texas Health Science Center Wake Forest University School of Medicine Professor of Medicine Chief, Lipoprotein and Metabolic Disorders Institute Harvard Medical School Michael Davidson, MD Sergio Fazio, MD, PhD Keith Ferdinand, MD Clinical Professor of Medicine Cornelius Vanderbilt Professor of Medicine Clinical Professor, Cardiology Division Director, Preventive Cardiology Professor of Pathology, Immunology Microbiology Emory University School of Medicine The University of Chicago Chief, Section of Cardiovascular Disease Prevention Chief Science Officer Pritzker School of Medicine Vanderbilt University Medical Center Association of Black Cardiologists Vivian Fonseca, MD JoAnne Foody, MD W. Timothy Garvey, MD Professor of Medicine and Pharmacology Medical Director Butterworth Professor and Chair Tullis Tulane Alumni Chair in Diabetes Cardiovascular Wellness Program Department of Nutrition Sciences Chief, Section of Endocrinology Brigham and Women’s Hospital University of Alabama at Birmingham Tulane University Health Sciences Center Associate Professor GRECC Investigator and Staff Physician Harvard Medical School Birmingham VA Medical Center Director, UAB Diabetes Research Training Center James Gavin III, MD, PhD Thomas Giles, MD Allison Goldfine, MD CEO Chief Medical Officer Clinical Professor of Medicine Associate Professor of Medicine Healing Our Village, Inc. Heart and Vascular Institute Harvard Medical School Clinical Professor of Medicine Tulane University School of Medicine Head, Clinical Behavioral Outcomes ResearchChairpersons Faculty Emory University School of Medicine Joslin Diabetes Center Irl Hirsch, MD Silvio Inzucchi, MD Terry Jacobson, MD Professor of Medicine Professor of Medicine Professor of Medicine, Emory University Division of Metabolism, Endocrinology Nutrition Clinical Director, Section of Endocrinology Dir., Office of Health Promotion Disease Prevention University of Washington School of Medicine Director, Yale Diabetes Center Co-Director, Lipid CV Risk Reduction Program Director, Endocrinology Metabolism Fellowship Grady Health Systems Lee M. Kaplan, MD, PhD Robert Kushner, MD Peter Libby, MD Associate Professor of Medicine Clinical Director Chief, Cardiovascular Medicine Harvard Medical School Northwestern Comprehensive Center on Obesity Brigham and Women’s Hospital Director, Obesity, Metabolism Nutrition Institute Professor of Medicine Mallinckrodt Professor of Medicine Massachusetts General Hospital Division of General Internal Medicine Harvard Medical School Northwestern Univ. Feinberg School of Medicine Peter McCullough, MD, MPH Luigi Meneghini, MD Suzanne Oparil, MD Chief Academic and Scientific Officer Professor of Clinical Medicine Professor of Medicine, Physiology Biophysics St. John Providence Health System Division of Endocrinology, Diabetes Metabolism Director, Vascular Biology Hypertension Program Director, Eleanor and Joseph Kosow Diabetes Division of Cardiovascular Disease Treatment Center, Diabetes Research Institute Department of Medicine University of Miami Miller School of Medicine University of Alabama at Birmingham “The CMHC has become the premier U.S. conference on cardiometabolic risk due to the expansive expertise 4 of an all-star faculty of both basic and clinical researchers.” – Irl Hirsch, MD
  11. 11. Robert H. Eckel, MD Jay S. Skyler, MD, MACP Professor of Medicine Professor of Medicine, Pediatrics, and Psychology Division of Endocrinology, Metabolism and Diabetes Division of Endocrinology, Diabetes and Metabolism Professor of Physiology and Biophysics University of Miami Miller School of Medicine Charles A. Boettcher II Chair in Atherosclerosis Deputy Director for Clinical and Academic Programs Director, Discovery Translation Diabetes Research Institute Colorado Clinical Translational Science Institute University of Colorado Anschutz Medical Campus Director, Lipid Clinic, University Hospital‹•–‹‰—‹•Š‡† ƒ…—Ž–› Anne Peters, MD Jorge Plutzky, MD Richard Pratley, MD Professor, Keck School of Medicine Associate Professor of Medicine Director, Florida Hospital Diabetes Institute Director, Clinical Diabetes Programs Harvard Medical School Senior Scientist, Translational Research Institute University of Southern California Director, Vascular Disease Prevention Program for Metabolism and Diabetes Brigham and Women’s Hospital Professor, Sanford Burnham Medical Research Inst. Matthew Riddle, MD Paul Ridker, MD, MPH Matthew Roe, MD Professor of Medicine Director, Center for Cardiovascular Associate Professor Oregon Health Science University Disease Prevention Duke University School of Medicine Brigham and Women’s Hospital Division of Cardiology Eugene Braunwald Professor of Medicine Duke University Medical Center Harvard Medical School Duke Clinical Research Institute Julio Rosenstock, MD Francesco Rubino, MD Donna Ryan, MD Clinical Professor of Medicine Chief, Gastrointestinal Metabolic Surgery Professor University of Texas Southwestern Medical School Associate Professor of Surgery Associate Executive Director for Clinical Research Director, Dallas Diabetes and Endocrine Center Director, Metabolic Diabetes Surgery Center Pennington Biomedical Research Center New York-Presbyterian Hospital Weill Cornell Medical Center Marc Sabatine, MD, MPH Ernst Schaefer, MD Arya Sharma, MD, PhD Chairman, TIMI Study Group Professor of Medicine Professor of Medicine Associate Physician, Cardiovascular Medicine Tufts University School of Medicine Chair, Obesity Research and Management Brigham and Women’s Hospital Senior Scientist and Director University of Alberta Associate Professor of Medicine Lipid Metabolism Laboratory Clinical Co-Chair Harvard Medical School Jean Mayer USDA HNRCA at Tufts University Alberta Health Services Obesity Program Domenic Sica, MD Steven Smith, MD Allan Sniderman, MD Professor, Internal Medicine, Nephrology Director, Translational Research Institute Professor of Cardiology Section Head Co-Director, Translational Research for DOC Mike Rosenbloom Lab. for Cardiovascular Research Clinical Pharmacology Hypertension Professor, Diabetes and Obesity Research Ctr. McGill University Health Center Virginia Commonwealth University Sanford Burnham Medical Research Institute Royal Victoria Hospital Gregg Stone, MD Neil Stone, MD, MACP Addison Taylor, MD, PhD Professor of Medicine, Columbia University Bonow Professor of Preventive Cardiology Professor of Medicine Director, Cardiovascular Research and Education Feinberg School of Medicine, Northwestern Univ. Chief, Div. of Hypertension Clinical Pharmacology Center for Interventional Vascular Therapy Medical Director, Vascular Center Dept. of Medicine, Baylor College of Medicine NY-Presbyterian Hosp., Columbia Univ. Medical Ctr. Bluhm Cardiovascular Institute Co-Director, Vascular Medicine Clinic Co-Director, Medical Research and Education Northwestern Memorial Hospital Michael E. DeBakey VA Medical Center The Cardiovascular Research Foundation Peter Toth, MD, PhD Sotirios Tsimikas, MD James A. Underberg, MD Director of Preventative Cardiology Professor of Medicine Clinical Assistant Professor of Medicine CGH Medical Center Director, Vascular Medicine NYU School of Medicine Professor, Clinical Family Community Medicine Division of Cardiovascular Diseases NYU Center for Prevention of Cardiovascular Disease Chairpersons Faculty University of Illinois College of Medicine University of California San Diego Director, Bellevue Hospital Lipid Clinic School of Medicine Alan Weder, MD William White, MD Stephen Wiviott, MD Professor, Division of Cardiovascular Medicine Professor and Chief, Division of Hypertension Assistant Professor of Medicine Department of Internal Medicine Clinical Pharmacology Harvard Medical School Co-Director, Vascular Medicine Program Pat and Jim Calhoun Cardiology Center Investigator, TIMI Study Group University of Michigan Medical Director, Clinical Trials Unit Associate Physician, Cardiovascular Division University of Connecticut School of Medicine Brigham and Women’s Hospital Carol Wysham, MD Bernard Zinman, MD Clinical Associate Professor of Medicine Director, Leadership Sinai Center for Diabetes University of Washington School of Medicine Mount Sinai Hospital Section Head, Rockwood Center for Professor of Medicine Diabetes and Endocrinology University of Toronto Collaborate with our expert faculty to decipher the most recent clinical data the immediate implications for your patients practice. 8th An “Integrated management of all aspects of cardiometabolic risk – from lifestyle modifications to supplements to prescription drugs – is the only way to approach this 21st-century epidemic. The CMHC brings it all together with 5 experts from multiple disciplines – providing the state of the art on this rapidly advancing area.” – Daniel Rader, MD
  12. 12. ʹͲͳʹ ƒ”†‹‘‡–ƒ„‘Ž‹… ‡ƒŽ–Š ‘‰”‡•• Agenda ‡†‡•†ƒ›ǡ …–‘„‡” ͳͲǡ ʹͲͳʹ 2:30 – 3:45pm Symposium “With the rising tide of the ‘epidemic’ in diabetes and obesity, we 4:00 – 5:15pm Symposium all need to monitor closely what is new to prevent an avalanche of cardiovascular disease. The Cardiometabolic Health Congress 6:30 – 8:30pm Dinner Symposia is the best way to stay on top of this increasingly important and critical field.” − Christopher Cannon, MD Š—”•†ƒ›ǡ …–‘„‡” ͳͳǡ ʹͲͳʹ 6:15 – 8:00am Breakfast Symposia 2:00 – 2:45pm Keynote Session Are We Ready for Bariatric Surgery 8:00 – 8:05am Opening Remarks as the Treatment of Choice for T2DM? Jay Skyler, MD Francesco Rubino, MD 8:05 – 9:15am Keynote Session 2:45 – 3:15pm Expanding Evidence that Obesity Cardiometabolic Health 2012: Can Be Successfully Managed Guideline Updates Implications by Behavioral Interventions for Clinical Practice Lawrence Appel, MD moderator: Robert Eckel, MD presenters: Silvio Inzucchi, MD; 3:15 – 4:15pm Afternoon Break/Exhibit Hall Suzanne Oparil, MD; Neil Stone, MD 4:15 – 4:45pm The Mechanistic and Therapeutic Link 9:15 – 9:45am Prevention of CVD in Patients Between Obesity and Diabetes: with Diabetes Where Are We Where Do We Need to Go? James Gavin III, MD Allison Goldfine, MD 9:45 – 10:15am Glycemic Control During and 4:45 – 5:30pm Integrating Evidence-Based Strategies After CCU/Inpatient Setting into Clinical Practice for the Management Irl Hirsch, MD of Patients with Obesity T2DM 10:15 – 11:15am Morning Break/Exhibit Hall moderator: Robert Eckel, MD panelists: Lawrence Appel, MD; 11:15am – 12:00pm T2DM 2012: Expert Recommendations James Gavin III, MD; Allison Goldfine, MD; Evidence-Based Strategies for Irl Hirsch, MD; Silvio Inzucchi, MD; Francesco Rubino, MD Achieving Optimal Results moderator: Jay Skyler, MD 5:30pm Closing Remarks panelists: James Gavin III, MD; Irl Hirsch, MD; Robert Eckel, MD Silvio Inzucchi, MD 5:45 – 6:45pm Welcome Reception 12:15 – 1:45pm Lunch Symposia 7:00 – 9:00pm Dinner SymposiumAgenda Agenda and faculty are subject to change. “Cardiometabolic risk is at the core of our efforts at preventing morbidity and mortality for our patients with type 2 diabetes. Addressing these challenges through a clear, effective and practical approach is 6 at the core of this program.” – Luigi Meneghini, MD
  13. 13. For Corporate-Supported o Sponsored Symposia e details, please see pages 8 9 ”‹†ƒ›ǡ …–‘„‡” ͳʹǡ ʹͲͳʹ6:15 – 8:00am Breakfast Symposium 3:15 – 4:15pm Afternoon Break/Exhibit Hall8:05 – 8:10am Opening Remarks 4:15 – 5:30pm Evaluation and Management Christie Ballantyne, MD of Kidney Function in Patients with CAD8:10 – 9:30am Keynote Session moderator: George Bakris, MD Inflammation Cardiometabolic Risk: presenters: Ron Blankstein, MD; Translating the Science into Peter McCullough, MD Clinical Practice moderator: Christie Ballantyne, MD 5:30pm Closing Remarks presenters: Peter Libby, MD; Paul Ridker, MD George Bakris, MD9:30 – 10:30am Morning Break/Exhibit Hall 6:00 – 8:00pm Dinner Symposium10:30 – 11:45am Late-Breaking Clinical Trials FDA Update: How Will the Latest Data Impact Clinical Practice? moderator: Robert Eckel, MD panelists: Christie Ballantyne, MD; Christopher Cannon, MD; Keith Ferdinand, MD; “As clinicians, we face many challenges in caring Jay Skyler, MD for the ever-increasing number of patients with12:00 – 1:30pm Lunch Symposia cardiometabolic risk. CMHC provides an invaluable opportunity to hear cutting-edge science, clinical1:45 – 3:15pm Clinical Controversies in Lipid perspectives and the newest information on Management: Viewpoints of managing CM risk.” – JoAnne Foody, MD Guidelines Case-Based Discussion moderator: Christie Ballantyne, MD panelists: Harold Bays, MD; Robert Eckel, MD; JoAnne Foody, MDƒ–—”†ƒ›ǡ …–‘„‡” ͳ͵ǡ ʹͲͳʹ6:15 – 8:00am Breakfast Symposium8:05 – 8:10am Opening Remarks Christie Ballantyne, MD8:10 – 9:15am Hot Topics in Thrombosis ACS moderator: Deepak L. Bhatt, MD “One of the major strengths of this program is the panelists: Peter Berger, MD; Matthew Roe, MD faculty’s incredible breadth and depth of knowledge about cardiometabolic risk. I rarely learn so much9:15 – 9:45am Comparative Approach to from a conference where I am also a speaker. I may Achieving BP Goals: How Many be biased, but I think this is a conference well worth Ways to Interpret the Data? attending.” – Anne Peters, MD George Bakris, MD9:45 – 10:00am Morning Break10:00am – 12:00pm Clinical Dilemmas Evidence-Based Solutions for HTN Management moderator: George Bakris, MD panelists: Domenic Sica, MD; Alan Weder, MD; William White, MD Agenda12:00pm Closing Remarks George Bakris, MD Agenda and faculty are subject to change. “The importance of diabetes as a risk factor for cardiovascular disease continues to grow. The CMHC nicely brings together all the different perspectives that are necessary to provide optimal care to reduce cardiovascular risk.” 7 – Deepak L. Bhatt, MD
  14. 14. ʹͲͳʹ ƒ”†‹‘‡–ƒ„‘Ž‹… ‡ƒŽ–Š ‘‰”‡•• Corporate-Supported Sponsored Symposia ‡†‡•†ƒ›ǡ …–‘„‡” ͳͲǡ ʹͲͳʹ 2:30 – 3:45pm 6:30 – 8:00pm Symposium (non-CME) Dinner Symposium (non-CME) Fixed-Dose Triple Combination Therapy New Treatment Options for Obesity for Patients with Uncontrolled Hypertension Donna Ryan, MD on Dual Combination Therapy Sponsored by Vivus, Inc. Robert Busch, MD, FACE Sponsored by Daiichi Sankyo, Inc. 6:30 – 8:30pm Dinner Symposium 4:00 – 5:15pm Personalized T2DM Management: Maximizing the Role Symposium (non-CME) of GLP-1 RA Therapy in the Continuum of Care The Evolving Landscape of Lipid Management Richard Bergenstal, MD; Robert Chilton, MD; Harold Bays, MD Anne Peters, MD; Carol Wysham, MD Sponsored by Amarin Corporation Supported by an educational grant from Amylin Pharmaceuticals, Inc. Š—”•†ƒ›ǡ …–‘„‡” ͳͳǡ ʹͲͳʹCorporate-Supported Sponsored Symposia 6:15 – 8:00am 12:15 – 1:45pm Breakfast Symposium Lunch Symposium Obesity Management 2012: Novel Targeting Statin Therapy 2012: Selecting the Right Pathway to of the CNS for Weight Loss, Glycemic Control Optimize Outcomes for Clinically Complex Patients Cardiovascular Risk Reduction Christie Ballantyne, MD; Michael Davidson, MD; Louis Aronne, MD; Robert Eckel, MD; JoAnne Foody, MD; Peter Toth, MD Robert Kushner, MD; Steven Smith, MD Supported by an educational grant from Supported by an educational grant from Eisai Inc. Kowa Pharmaceuticals America, Inc. and Lilly USA, LLC 6:15 – 8:00am 7:00 – 9:00pm Breakfast Symposium Dinner Symposium Intensive Glycemic Control CV Risk Reduction: GLP-1 Agonist Therapy 2012: The Impact of Early Insulin Therapy on Macrovascular Cutting-Edge Data and Clinical Implications Outcomes in Patients with Dysglycemia for the Spectrum of Patients with T2DM Richard Bergenstal, MD; Vivian Fonseca, MD; Vivian Fonseca, MD; Richard Pratley, MD; Jorge Plutzky, MD; Matthew Riddle, MD Julio Rosenstock, MD; Bernard Zinman, MD Supported by an educational grant from Supported by an educational grant from Novo Nordisk, Inc. Sanofi-aventis U.S. Inc., A SANOFI COMPANY 12:15 – 1:45pm Lunch Symposium Basal Insulin 2012: A New Generation of Strategies to Optimize Glucose Control Timothy Bailey, MD; Irl Hirsch, MD; Luigi Meneghini, MD; Bernard Zinman, MD Supported by an educational grant from Novo Nordisk, Inc. Agenda and faculty are subject to change. “The CMHC has rapidly become the most illuminating annual forum for updates on the mechanisms underlying the 8 global scourge confronting populations worldwide, and the scientific basis of rational prevention and treatment paradigms.” – Om Ganda, MD
  15. 15. Corporate-Supported Sponsored Symposia ”‹†ƒ›ǡ …–‘„‡” ͳʹǡ ʹͲͳʹ6:15 – 8:00am 6:00 – 8:00pmBreakfast Symposium Dinner SymposiumA Closer Look at Severe and Familial State-of-the-Art Management of Mixed Dyslipidemia Hypercholesterolemia: Expert Analysis of Residual CV Risk: Expert Analysis on the Emerging Role ofPathophysiology and the Role of Apo B Inhibition Omega-3 Fatty AcidsSergio Fazio, MD; Allan Sniderman, MD; Harold Bays, MD; Deepak L. Bhatt, MD; William Cromwell, MD;Sotirios Tsimikas, MD; James A. Underberg, MD Terry Jacobson, MD; Ernst Schaefer, MDSupported by an educational grant from Genzyme Corporation Supported by an educational grant from Amarin Corporation12:00 – 1:30pmLunch Symposium ƒ–—”†ƒ›ǡ …–‘„‡” ͳ͵ǡ ʹͲͳʹAdvances in Weight-Loss Management:Examining the Clinical Impact of Novel Therapieson Obesity, Diabetes Cardiometabolic Risk 6:15 – 8:00am Breakfast SymposiumRobert Eckel, MD; W. Timothy Garvey, MD;Lee M. Kaplan, MD; Jorge Plutzky, MD; Arya Sharma, MD Expert Perspectives on Endothelial Function, HTN, and CV Risk: Cutting-Edge Data on theSupported by an educational grant from Vivus, Inc. Impact of Novel Beta Blockers along the HTN Continuum of Care Corporate-Supported Sponsored Symposia12:00 – 1:30pm George Bakris, MD; Keith Ferdinand, MD;Lunch Symposium Thomas Giles, MD; Addison Taylor, MDExpert Analysis of Innovative Antiplatelet Data: Supported by an educational grant fromClinical Implications for Patients with ACS Forest Laboratories, Inc.Undergoing PCIChristopher Cannon, MD; Marc Sabatine, MD;Gregg Stone, MD; Stephen Wiviott, MDSupported by an educational grant fromDaiichi Sankyo, Inc. and Eli Lilly and Company Agenda and faculty are subject to change. Ž› ʹͲͳʹ ’ƒ”–‹…‹’ƒ–• ƒ› ”‡‰‹•–‡” ˆ‘” …‘”’‘”ƒ–‡Ǧ•—’’‘”–‡† Ƭ •’‘•‘”‡† •›’‘•‹ƒǤ ‡ƒ–‹‰ ‹• Ž‹‹–‡† ƒ† ƒ˜ƒ‹Žƒ„Ž‡ ‘ ƒ ϔ‹”•–Ǧ…‘‡ǡ ϔ‹”•–Ǧ•‡”˜‡ „ƒ•‹•Ǥ ‘” •›’‘•‹ƒ —’†ƒ–‡• ƒ† ƒ††‹–‹‘•ǡ ’Ž‡ƒ•‡ ˜‹•‹– ™™™Ǥ…ƒ”†‹‘‡–ƒ„‘Ž‹…Š‡ƒŽ–ŠǤ‘”‰Ȁƒ‰‡†ƒǤƒ•’ “Cardiometabolic health, including the control of associated cardiovascular risk factors, is a prominent challenge globally to medicine now and in the future. Furthermore, it is essential to better define which patients are at greatest risk for 9 cardiovascular morbidity and mortality, and how best to curtail that risk.” − Keith Ferdinand, MD
  16. 16. ʹͲͳʹ ƒ”†‹‘‡–ƒ„‘Ž‹… ‡ƒŽ–Š ‘‰”‡•• Program Overview –ƒ–‡‡– ‘ˆ ‡‡†ȗ ƒ”‰‡– —†‹‡…‡ Ƭ ‡ƒ”‹‰ „Œ‡…–‹˜‡• The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care professionals in the United States. The CMHC is designed for advanced-level clinicians responsible The prevalence of most cardiometabolic risk factors – especially for the prevention, diagnosis, and management of hypertension, diabetes, and obesity – continues to rise. In the years cardiometabolic risk. ahead, American physicians should expect to treat unprecedented At the end of the Congress, participants will be able to: numbers of patients at high risk for morbidity and mortality from cardiovascular disease. In 2000, approximately 32% of U.S. adults • Explain the interrelationships among the various had the metabolic syndrome, a constellation of cardiometabolic cardiometabolic risk factors, their impact on cardiovascular risk factors including excessive abdominal fat, insulin resistance, health, and their common comorbidities. dyslipidemia, and hypertension. Today, that figure has climbed to 34% and may even be as high as 38%, depending on the criteria • Translate evidence-based strategies for prevention, screening, used to define the syndrome. and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice. Cardiometabolic Risk Factors Are Undertreated and Difficult to Manage • Identify which interventions, including lifestyle changes Despite the well-documented risks of unchecked diabetes, obesity, and various drugs in combination, are most appropriate for hypertension, and dyslipidemia, these conditions are commonly particular patients based on their risk profiles. undertreated. Even when treated, they remain stubbornly difficult • Identify how novel and emerging therapies can be integrated to manage. into clinical practice to reduce morbidity and mortality from • Half or more of treated patients with diabetes fail to meet cardiovascular and metabolic disease. recommended target HbA1c goals. Analyses of data from National Health and Nutrition Examination surveys found that only one-half to one-third of treated patients achieve the Conclusion American Diabetes Association’s recommended HbA1c target Healthcare professionals play a major role in stemming the of 7% or less. In addition, a report released by the American future burden of cardiovascular disease, diabetes, and associated Association of Clinical Endocrinologists stated that two out comorbidities by employing aggressive strategies for the early of three patients with type 2 diabetes were not achieving the identification and comprehensive management of patients Association’s recommended HbA1c goal of 6.5% or less. presenting with multiple cardiometabolic risk factors. The 2012 • When it comes to first-line therapy for obesity – diet and Cardiometabolic Health Congress will translate the latest exercise – few patients succeed, and any improvements are cutting-edge medical research into practical, clinical approaches usually modest. Current pharmacotherapy options are limited. for preventing, delaying, and managing cardiovascular and Available obesity drugs have, to date, produced only modest metabolic risk. The goal is to provide the medical community weight loss in most patients and have been linked to adverse with evidence-based interventions to improve health outcomes gastrointestinal effects and mood disorders. Furthermore, and quality of life for the growing numbers of patients at increased many clinicians do not address diet and exercise for weight loss cardiometabolic risk. with their patients, citing a lack of belief that lifestyle changes can work, lack of understanding of how to counsel patients Purpose Statement about lifestyle change, and inadequate amounts of time and The goal of the Congress is to improve patient outcomes through personnel. early identification and intervention strategies for patients with, • Only 71% of patients with hypertension are receiving any form or at risk of developing, diabetes and cardiovascular disease. of treatment. Of these, less than half (48%) have their blood pressure under control; hypertension remains uncontrolled in 52% of treated patients. * To access the 2012 CMHC full statement of need and reference list, please visit Overview • Less than half of those who qualify for any kind of lipid-modifying treatment to reduce their risk of coronary heart disease are receiving it. In fact, less than half of even the highest-risk individuals – those with symptomatic coronary heart disease – are receiving lipid-lowering treatment. Of those being treated, only about one-third are achieving target goals. ƒ˜‡ –Š‡ Ǩ The CMHC presents... Cardiometabolic Week 10
  17. 17. Accreditation Information ƒ” ʹͺǤͷ ”‡†‹–•Physician AccreditationThis activity has been planned and implemented in accordancewith the Essential Areas and policies of the Accreditation Councilfor Continuing Medical Education through the joint sponsorshipof Medical Education Resources and HealthScience Media, Inc.Medical Education Resources is accredited by the ACCME toprovide continuing medical education for physicians. Credit Designation Medical Education Resources designates this live activity for a maximum of 28.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.AAFP – American Academy of Family PhysiciansThis Live activity, 2012 Cardiometabolic Health Congress, with a beginning date of 10/10/12, has been reviewed and is acceptable forup to 20.0 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensuratewith the extent of their participation in the activity.American Academy of Nurse PractitionersPending approval from the American Academy of Nurse Practitioners.Nursing AccreditationMedical Education Resources is accredited as a provider of continuing nursing education by the American Nurses CredentialingCenter’s Commission on Accreditation.This CE activity provides 28.5 contact hours of continuing nursing education.Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing,Provider #CEP 12299, for 28.5 contact hours.Registered Dietitian AccreditationMedical Education Resources (Provider Number ME110) is a Continuing Professional Education (CPE) Accredited Provider withthe Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive28.5 continuing professional education units (CPEUs) for completion of this program/material.Pharmacy Accreditation Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 28.5 contact hour(s) (2.85 CEUs) of the Accreditation Council for Pharmacy Education.(Universal Program Number - 0816-9999-12-005-L01-P)There is a registration fee for this educational activity.This activity is certified as Knowledge based CPE.Attention Certified Diabetes Educators: The 2012 Cardiometabolic Health Congress (CMHC) is accredited by Medical Education Accreditation InformationResources (MER). MER is accredited by the ACCME, ANCC, ACPE, and the CDR to provide continuing medical education credits.All of these accredited organizations are recognized by the AADE when applying for CDE renewal of certification or for initial certification.Disclosure of Conflicts of InterestIt is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educationalactivities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individualswho are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to,reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. 11
  18. 18. ʹͲͳʹ ƒ”†‹‘‡–ƒ„‘Ž‹… ‡ƒŽ–Š ‘‰”‡•• Supporters Sponsors ••‘…‹ƒ–‹‘ —’’‘”–‡”• Current Members of Our Association Supporters Receive a $100 Discount! (5,$1 $0 ,125325$7( $1 ,2 1 2/ EĞǁ :ĞƌƐĞLJ ŽŽƌĚŝŶĂƟŶŐ ,7 ( / *( 5 ŽĚLJ ŽĨ 2) 1 87 ‡”‹…ƒ ‡ƒ”– ••‘…‹ƒ–‹‘ ŽƵŶĐŝůƐ ŽŶ ,ŝŐŚ ůŽŽĚ WƌĞƐƐƵƌĞ ZĞƐĞĂƌĐŚ͖ ^ƚƌŽŬĞ͖ ƉŝĚĞŵŝŽůŽŐLJ Θ WƌĞǀĞŶƟŽŶ͖ s ŝƐĞĂƐĞ ŝŶ ƚŚĞ zŽƵŶŐ͖ ĂƐŝĐ s ^ĐŝĞŶĐĞƐ͖ EƵƚƌŝƟŽŶ͕ WŚLJƐŝĐĂů ĐƟǀŝƚLJ Θ DĞƚĂďŽůŝƐŵ͖ Association of Physicians Assistants s EƵƌƐŝŶŐ͖ ůŝŶŝĐĂů ĂƌĚŝŽůŽŐLJ͖ in Cardiology ŝĚŶĞLJ ŝŶ s ŝƐĞĂƐĞ ‡–”‘’‘Ž‹–ƒ ‡™ ‘” ••‘…‹ƒ–‹‘ ‘ˆ ‹ƒ„‡–‡• †—…ƒ–‘”• ^ĂŶ ƌĂŶĐŝƐĐŽ ĂLJ ƌĞĂ ƐƐŽĐŝĂƟŽŶ ŽĨ ŝĂďĞƚĞƐ ĚƵĐĂƚŽƌƐ TM —„Ž‹…ƒ–‹‘ —’’‘”–‡”•Supporters Sponsors12
  19. 19. Supporters SponsorsThe 2012 CMHC gratefully acknowledges the educational grant support and sponsorship provided by the following organizations. Žƒ–‹— —’’‘”–‡”• ‘Ž† —’’‘”–‡”• ‘Ž† ’‘•‘”• Supporters Sponsors ‹Ž˜‡” —’’‘”–‡” ”‘œ‡ —’’‘”–‡” ”‘œ‡ ’‘•‘”• †—…ƒ–‹‘ƒŽ —’’‘”–‡”• 13
  20. 20. 2012 Exhibitors Travel Information ʹͲͳʹ šŠ‹„‹–‘”• (as of 7/18/12) Aegerion Pharmaceuticals Gilead Sciences, Inc. Akrimax Pharmaceuticals Health Diagnostic Laboratory, Inc. Amarin Corporation Kowa Pharmaceuticals America, Inc./Lilly USA, LLC Athera Biotechnologies LipoScience Atherotech Merck Company Boehringer Ingelheim Pharmaceuticals, Inc. Metagenics Boston Heart Diagnostics Novo Nordisk, Inc. Daiichi Sankyo Otsuka America Pharmaceutical Inc. diaDexus Pure Encapsulations Eisai sanofi EndoPAT/Itamar Medical Inc. sanofi diabetes Endurance Products Co. Santarus, Inc. Ethicon Endo-Surgery SleepImage Everidis Health Sciences Tethys Forest Pharmaceuticals, Inc. VIVUS, Inc. Genzyme XYMOGEN ’‘•‘”•Š‹’ ’’‘”–—‹–‹‡• Don’t Miss this Unprecedented Opportunity to Reach 1500 U.S.-Based Practicing Clinicians! Becoming a sponsor of the 2012 CMHC will provide your company valuable exposure to endocrinologists, cardiologists, and2012 Exhibitors Travel Information primary care physicians who are on the front line – managing patients with multiple cardiometabolic risk factors. ‘–‡Ž Ƭ ”ƒ˜‡Ž
  21. 21. ˆ‘”ƒ–‹‘ Sponsorship and exhibit opportunities are offered on a first-come, first-served basis. For more information please contact us at Westin Boston Waterfront Hotel 425 Summer Street 877.571.4700 Boston, MA 02210 (617) 532-4600 The Westin Boston Waterfront Hotel is located in Boston’s artfully revitalized waterfront district and is less than three miles from Logan International Airport. ‘’Ž‹‡–ƒ”› Ž‹‡ To book your hotel room, please contact the hotel directly. Mention that you are attending the 2012 Cardiometabolic Health Congress to receive our special The CMHC offers complimentary negotiated room rate. online CME activities featuring multimedia presentations. The 2012 Cardiometabolic Health Congress discounted room rate is available only until October 3, 2012, on a first-come, first-served basis. Rooms are limited Visit and subject to availability. For instructions on how to book your hotel accommodations online, visit to get started. “The CMHC is remarkable for its broad range of topics pertinent to cardiometabolic diseases. This meeting 14 is an excellent opportunity for busy professionals to get a comprehensive update from leaders in the field.” – Richard Pratley, MD
  22. 22. Register by 9/14/2012 and Save Up to $300!Registration Form 4 Easy Ways to Register ͚͙͚͘ Online: Fax: 866.218.9168 Phone: Mail Registration Form with Payment: Brittany at 877.571.4700 2012 Cardiometabolic Health Congress 732.758.0030 - outside the USA c/o Health Science Media, Inc. 788 Shrewsbury Avenue, Suite 102 Tinton Falls, NJ 07724 Early Bird Discount Register by Onsite Registration‡‰‹•–”ƒ–‹‘ ‡‡• Register by 9/14/2012 10/8/2012 After 10/8/2012Physicians* $695 $795 $895Allied Health Professionals* $595 $695 $795Residents/Fellows** $250 $300 $350Industry $1095 $1295 $1395* Must be engaged in clinical practice to receive discounted rate.** ID card from school, residency, or fellowship program is required for verification. No other discounts apply.Prefix First Name Last Name Degree(s)TitleAffiliation Register by 9/14/2012 and Save Up to $300!Address 1Address 2City State Zip CodeTel FaxEmailPlease indicate your specialty (check one): Cardiology Endocrinology Internal Medicine Nephrology Primary Care Industry OtherWhich best describes your primary workplace setting? (check one): Office-based Hospital Academic Government Pharmacy IndustryCurrent members of our Association Supporters receive a $100 discount off the registration price.Indicate which association you are a member of below: Alliance of Cardiovascular Professionals (ACVP) Association of Black Cardiologists (ABC) National Association of Chronic Disease Directors (NACDD) American Academy of Pediatrics (AAP) Association of Occupational Health Professionals in Healthcare (AOHP) National Kidney Foundation (NKF) Registration Form American Association of Heart Failure Nurses (AAHFN) Association of Physician Assistants in Cardiology (APAC) New Jersey Coordinating Body of AADE (NJCB) American College of Cardiology Foundation (ACC) Connecticut Alliance of Diabetes Educators (CADE) Obesity Action Coalition (OAC) American College of Nutrition (ACN) Coordinating Body of AADE of Massachusetts (DEEM) The Obesity Society (TOS) American College of Preventive Medicine (ACPM) The Endocrine Society (ENDO) San Francisco Bay Area Association of Diabetes Educators (SFBAADE) American Heart Association (AHA) International Association for the Study of Obesity (IASO) Society of Atherosclerosis Imaging and Prevention (SAIP) American Society of Bariatric Physicians (ASBP) International Society on Hypertension in Blacks (ISHIB) Society of Cardiovascular Computed Tomography (SCCT) American Society of Endocrine PAs (ASEPA) Latino Diabetes Association (LDA) Society for the Study of Ingestive Behavior (SSIB) American Society of Hypertension (ASH) Metropolitan New York Local Networking Group of the AADE (MNYADE) Vascular Disease Foundation (VDF) National Association of Bariatric Nurses (NABN) World Heart Federation (WHF)Total Amount DueMethod of Payment Check Visa MasterCard American Express DiscoverAccount Number Expiration DateCardholder Name Cardholder SignatureCancellation PolicyCancellations must be made in writing via fax to 866.218.9168 or email to Refunds, less a $100 service fee, will be given if writtencancellation is received no later than September 7, 2012. No refunds will be given after September 7, 2012. To send a substitute, please call 877.571.4700 or email 15your request to
  23. 23. 2012 Cardiometabolic Health Congressc/o HealthScience Media, Inc.788 Shrewsbury Avenue, Suite 102Tinton Falls, NJ 07724 ͚͙͚͘ 7th Annual The Premier Multidisciplinary Expert-Level Forum 7th Annual Best Cardiometabolic Science Clinical Education Providing the October 10 –13, 2012 • Westin Boston Waterfront Hotel • Boston, MA Members of CMHC Association Supporters Receive an Additional $100 Discount! ‡–”‘’‘Ž‹–ƒ ‡™ ‘” ••‘…‹ƒ–‹‘ ‘ˆ ‹ƒ„‡–‡• †—…ƒ–‘”• ‡”‹…ƒ ‡ƒ”– ••‘…‹ƒ–‹‘ ŽƵŶĐŝůƐ ŽŶ EƵƚƌŝƟŽŶ͕ WŚLJƐŝĐĂů ĐƟǀŝƚLJ Θ DĞƚĂďŽůŝƐŵ͖ ,ŝŐŚ ůŽŽĚ WƌĞƐƐƵƌĞ ZĞƐĞĂƌĐŚ͖ ^ƚƌŽŬĞ͖ ƉŝĚĞŵŝŽůŽŐLJ Θ WƌĞǀĞŶƟŽŶ͖ s ŝƐĞĂƐĞ ŝŶ ƚŚĞ zŽƵŶŐ͖ ĂƐŝĐ s ^ĐŝĞŶĐĞƐ͖ s EƵƌƐŝŶŐ͖ TM ůŝŶŝĐĂů ĂƌĚŝŽůŽŐLJ͖ ŝĚŶĞLJ ŝŶ s ŝƐĞĂƐĞ ǁǁǁ͘ĂŵĞƌŝĐĂŶŚĞĂƌƚ͘ŽƌŐ ^ĂŶ ƌĂŶĐŝƐĐŽ ĂLJ ƌĞĂ ƐƐŽĐŝĂƟŽŶ ŽĨ ŝĂďĞƚĞƐ ĚƵĐĂƚŽƌƐ (5,$1 $0 ,125325$7( $1 EĞǁ :ĞƌƐĞLJ ŽŽƌĚŝŶĂƟŶŐ ,2 1 2/ ŽĚLJ ŽĨ Association of Physicians Assistants ,7 ( / in Cardiology *( 5 2) 1 87 Earn up to 28.5 CME Credits! Customize Your CMHC Learning Experience Choose from 15 sessions and 14 complimentary symposia “The CMHC is the nation’s leading “The firestorm of diabetes and metabolic syndrome continues to spread with meeting advancing knowledge on the increasing incidence of hypertension and hypercholesterolemia acting like cardiometabolic health.” gasoline to further fuel the flames and contribute to higher CV morbidity and – Peter McCullough, MD mortality. The CMHC is the place to get the latest information on quelling this epidemic.” − George Bakris, MD “CMHC brings together a unique assemblage of basic, “It is striking that the CMHC has become the undisputed translational, and clinical experts with a diverse and leader in conferences that address the most important attentive audience to address an urgent contemporary metabolic derangements of our time, due largely to the health challenge that demands such a multidisciplinary strength of the faculty and their interactions with an approach.” − Peter Libby, MD engaged audience.” – James Gavin III, MD ‘‹ ͸Ͳ ‡š’‡”– ˆƒ…—Ž–›ǡ ͳͷͲͲ …‘ŽŽ‡ƒ‰—‡• Ƭ ͵ʹ ‡†‹…ƒŽ ƒ••‘…‹ƒ–‹‘• –‘ …‘„ƒ– –Š‡ ‰Ž‘„ƒŽ Š‡ƒŽ–Š …”‹•‹• ‡ƒƒ–‹‰ ˆ”‘ …ƒ”†‹‘˜ƒ•…—Žƒ” Ƭ ‡–ƒ„‘Ž‹… †‹•‡ƒ•‡Ǥ ™™™Ǥ…ƒ”†‹‘‡–ƒ„‘Ž‹…Š‡ƒŽ–ŠǤ‘”‰ This activity is jointly sponsored by HealthScience Media, Inc. (HSM), and Medical Education Resources, Inc. (MER).